Your browser doesn't support javascript.
loading
How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
Alan, Ozkan; Kuzhan, Okan; Koca, Sinan; Telli, Tugba Akin; Basoglu, Tugba; Ercelep, Ozlem; Filinte, Deniz; Sengul, Yildiz; Arikan, Huseyin; Kaya, Serap; Babacan, Nalan Akgul; Dane, Faysal; Yumuk, Perran Fulden.
Afiliação
  • Alan O; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Kuzhan O; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Yeditep University, Istanbul, Turkey.
  • Koca S; Division of Medical Oncology, Umraniye Research and Training Hospital, Istanbul, Turkey.
  • Telli TA; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Basoglu T; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Ercelep O; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Filinte D; Department of Pathology, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Sengul Y; Department of Radiology, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Arikan H; Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Kaya S; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Babacan NA; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Dane F; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
  • Yumuk PF; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
J Oncol Pharm Pract ; 26(4): 1011-1018, 2020 Jun.
Article em En | MEDLINE | ID: mdl-31615346
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Translocação Genética / Crizotinibe / Quinase do Linfoma Anaplásico / Neoplasias de Tecido Muscular / Antineoplásicos Limite: Adult / Child / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Translocação Genética / Crizotinibe / Quinase do Linfoma Anaplásico / Neoplasias de Tecido Muscular / Antineoplásicos Limite: Adult / Child / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article